INTRODUCTION
Diabetic macular edema (DME) is a frequent manifestation of diabetic retinopathy that occurs when the retina swells owing to fluid leakage from the macular capillary bed [1, 2] . DME can lead to visual impairment and, if left untreated, blindness. It is associated with reductions in health-related quality of life and can result in a substantial socioeconomic burden [3, 4] .
Until recently, laser photocoagulation monotherapy was the standard of care for DME. Laser monotherapy provides vision stabilization in patients with DME, but offers limited clinically significant improvements in vision [5] . Anti-vascular endothelial growth factor (VEGF) treatments have become available and are now the standard of care for these patients, offering a better prognosis [6] .
Ranibizumab, an anti-VEGF-A agent, was the first therapy to receive approval for the treatment of DME [approved by the European Medicines Agency (EMA) in January 2011] [7] .
Another anti-VEGF agent, aflibercept, was approved by the EMA for this indication in August 2014 [8] .
The approved regimens in the European Union of ranibizumab 0.5 mg pro re nata (PRN) and aflibercept 2.0 mg every 8 weeks have not been compared directly in the same clinical trial.
The only study comparing ranibizumab with aflibercept in patients with DME is the DRCR-net Protocol T trial (ClinicalTrials.gov identifier: NCT01627249) [9] . In Protocol T, patients receiving aflibercept gained, on average, 2.1 letters more than patients receiving ranibizumab (P = 0.03). Importantly, that study used a dose of ranibizumab (0.3 mg PRN) that is lower than the dose approved outside the United States (0.5 mg PRN). Therefore, the relative effects of ranibizumab 0.5 mg PRN and aflibercept 2.0 mg every 8 weeks remain unclear. In fact, the National Institute for Health and Care Excellence considered that ''the results (of Protocol T) could not be considered in its decision making'' when appraising ranibizumab 0.5 mg PRN versus aflibercept 2.0 mg every 8 weeks [10] . Therefore, we performed a cross-trial, indirect comparison incorporating patient-level statistical modeling to compare the visual outcomes of these two treatment regimens. We used clinical trials that compared ranibizumab 0.5 mg PRN (RESPOND [11] and RESTORE [12] ; ClinicalTrials.gov identifiers: NCT01135914 and NCT00687804, respectively) or aflibercept 2.0 mg every 8 weeks (VIVID-DME and VISTA-DME; ClinicalTrials.gov identifiers: NCT01331681 and NCT01363440, respectively) [13] with laser monotherapy. Table 1 shows the reported increases in best-corrected visual acuity (BCVA) for each trial, as measured by a gain of letters on the Early Treatment Diabetic Retinopathy Study scale [14] . The description of each trial can be found in the online supplementary material.
METHODS
A methodology similar to that described here has been used in a previous indirect comparison study [15] ; this approach represents a robust procedure for comparing ranibizumab and aflibercept for the treatment of DME. The basic idea behind the model was to leverage the patient-level information in RESPOND/ RESTORE to determine the relationships between baseline characteristics, treatment and BCVA change from baseline to month 12.
Once those relationships had been established, one could predict the outcome of the RESPOND/RESTORE clinical trials if the patients had different baseline characteristics to those in the actual trials.
Base Case Model (Model 1)
The analysis consisted of four steps.
Step 1: Identification of Confounders Published literature was used to identify baseline characteristics considered most likely Table 1 Mean gain in BCVA (number of letters) from baseline to month 12, as reported in each of the four published trials RESPOND [11] , RESTORE [12] , VIVID-DME, and VISTA-DME [13] For all reported results, missing data were handled using the last observation carried forward approach. For RESTORE, VIVID-DME, and VISTA-DME, patient data in this table match the published data [12, 13] . The published data for RESPOND were based on only patients who had measurements at month 12, and showed a mean BCVA gain at month 12 of 8.9 letters for ranibizumab monotherapy and 0.3 letters for laser monotherapy [11] BCVA best-corrected visual acuity, PRN pro re nata, SD standard deviation, VEGF vascular endothelial growth factor a Either ranibizumab or aflibercept, depending on the trial to predict a gain in BCVA at 12 months.
Predictors reported to correlate negatively with a gain in BCVA included baseline BCVA [16] , central retinal thickness (CRT) [17] , and age [16] . Baseline BCVA and CRT differed significantly between RESPOND [11]/RESTORE [12] and VIVID-DME/VISTA-DME [13] (Table 2) ; these factors were included in the base case model. Age was excluded because mean age did not differ significantly between patients in RESPOND/RESTORE and VIVID-DME/ VISTA-DME ( Table 2 ). In RESTORE, it was
shown that the impact on the outcomes of some baseline characteristics, especially CRT, was different between patients receiving ranibizumab and those receiving laser [12] .
Therefore, this model also included interaction terms between baseline characteristics and treatment.
Step 2: Regression Model
The RESPOND and RESTORE patient-level data were appended. A patient-level model analyzed change in BCVA from baseline to month 12 as a function of the baseline values:
Here, Y i represents the change in BCVA from baseline to month 12 [last observation carried Table 2 Baseline data for RESPOND [11] , RESTORE [12] , VIVID-DME, and VISTA-DME [13] Variables Anti-VEGF monotherapy P value Laser monotherapy P value
RESPOND/ RESTORE
VIVID-DME/ VISTA-DME
VIVID-DME/ VISTA-DME Data show mean (standard deviation) unless otherwise indicated Means were based on weighted averages (weights: patient numbers). Pooled variance for two arms in trial 1 and trial 2 (with n 1 and n 2 patients and variances Var 1 and Var 2 , respectively) was calculated using the following formula: (n 1 -1) 9 Var 1 ? (n 2 -1) 9 Var 2 /(n 1 ? n 2 -2) Statistical analyses: for continuous variables, P values were calculated using a t test (independent samples); for dichotomous variables, P values were calculated using a v 2 test BCVA best-corrected visual acuity, CRT central retinal thickness, HbA 1c glycated hemoglobin, ns not significant, VEGF vascular endothelial growth factor VIVID-DME/VISTA-DME, two models were used: one model with treatment and baseline BCVA as variables and another with treatment and baseline CRT as variables.
Step 3: Predicting Gains in BCVA After
Ranibizumab Treatment Using VIVID-DME/ VISTA-DME Mean Baseline Characteristics Baseline values from the aflibercept arms in VIVID-DME/VISTA-DME were substituted into the above model to give an estimate of the change in BCVA from baseline to month 12 for ranibizumab monotherapy, assuming that mean patient characteristics in RESPOND were similar to those in VIVID-DME/VISTA-DME. Baseline values from the laser monotherapy arms in VIVID-DME/VISTA-DME were used to predict the mean response for patients receiving this treatment.
Step
4: Indirect Treatment Comparison
The predicted gains in BCVA with ranibizumab monotherapy and laser monotherapy were used to compare ranibizumab with aflibercept indirectly, using a Bucher method [18] .
Base Case Model (Model 1) Validation
A number of analyses were conducted to assess the robustness of the results, which are presented in the online supplementary material.
Sensitivity Analyses (Models 2-6)
Sensitivity analyses were performed to ensure that the selection of independent variables was unbiased.
Full Model (Model 2)
In the first sensitivity analysis, a model was created that included the trial in which the patient participated, baseline variables commonly collected in clinical trials for DME (BCVA, CRT, age, sex, mean HbA 1c level, mean duration of diabetes) and the interaction terms between trial, baseline characteristics and treatment.
Stepwise Selection Model (Model 3)
In the second sensitivity analysis, an automated backward selection process was used to select variables based on their significance level.
Selected variables were kept in the model if their P value was \0.10. The rationale behind using an automated variable selection process was to remove potential author bias.
Baseline BCVA 24-73 Letters Model (Model 4)
Patients were eligible for enrolment in VIVID-DME/VISTA-DME only if their baseline BCVA was 24-73 letters. The impact of analyzing only patients in RESPOND/RESTORE with a baseline BCVA of 24-73 letters was assessed.
RESTORE CRT Adjustment Model (Model 5)
In RESTORE, optical coherence tomography (OCT) was performed at every study visit using Stratus OCT (Carl Zeiss Meditec, Dublin, CA, USA), which is a time-domain OCT (TD-OCT). More recent studies (VIVID-DME/VISTA-DME) [13] used Cirrus OCT (Carl Zeiss Meditec), which is a spectral-domain OCT (SD-OCT) [19] . Because it has been shown that CRT values can be lower when measured with TD-OCT than with SD-OCT [20, 21] , the RESTORE baseline CRT measurements were converted into SD-CRT values using published data linking Stratus OCT and Cirrus OCT measurements [20] . Specifically, RESTORE baseline CRT was increased by a mean of 
Compliance with Ethics Guidelines
The RESPOND and RESTORE studies were conducted in accordance with the Declaration of Helsinki and were approved by the ethics committee or institutional review board of each participating center.
RESULTS

Base Case Model (Model 1)
For all treatments, model 1 showed that higher baseline BCVA was associated with lower visual acuity gains at 12 months (P\0.05; Table 3 ). The impact of baseline BCVA on BCVA gain did not significantly differ between laser monotherapy, ranibizumab monotherapy, and combination therapy (P = 0.53). Higher CRT values at baseline were associated with significantly lower BCVA gains at 12 months for laser monotherapy (P\0.001; Table 3 ). This was not observed for ranibizumab monotherapy or combination therapy (P = 0.12 and P = 0.49, respectively).
In the base case model (model 1), the mean predicted gain with ranibizumab monotherapy was 8.7 letters (95% CI: 7.0-10.5). The mean predicted gain with combination therapy was also 8.7 letters (95% CI: 6.9-10.6), while there was a mean predicted loss with laser monotherapy of -1.1 letters (95% CI: -3.0 to 0.7). The incremental gain with ranibizumab monotherapy compared with laser monotherapy was 9.9 letters (95% CI: 7.3-12.4; Table 4 ; Fig. 1 ).
When the non-significant interaction between baseline BCVA and treatment was removed, the Table 4 ).
When the model included baseline BCVA, treatment and interaction between treatment and BCVA, but not baseline CRT, the incremental gain using ranibizumab monotherapy compared with laser monotherapy was 7.7 letters (95% CI: 5.3-10.0). When the model included baseline CRT, treatment and interaction terms, but not baseline BCVA, the incremental gain using ranibizumab monotherapy compared with laser monotherapy was 9.3 letters (95% CI:
6.8-11.9; Table 4 ).
Sensitivity Analyses
The estimates of the coefficients for the full model (model 2), the stepwise selection model (model 3), and the baseline BCVA 24-73 letters model (model 4) are shown in Table 3 . Table 4 Predicted mean gain in BCVA (number of letters) with ranibizumab over laser monotherapy at month 12 if patients in RESPOND/RESTORE [11, 12] had the same baseline characteristics as patients in VIVID-DME/VISTA-DME [13] Model Mean difference in number of letters 95% CI
Base case model (model 1) 9. First assumption: patients receiving ranibizumab have the same mean baseline characteristics as those on aflibercept in VIVID-DME/VISTA-DME [13] . Second assumption: patients receiving laser monotherapy have the same mean baseline characteristics as those on laser monotherapy in VIVID-DME/VISTA-DME [13] BCVA best-corrected visual acuity, CI confidence interval, CRT central retinal thickness
Using model 2, the predicted incremental gain in BCVA with ranibizumab over laser monotherapy was 10.1 letters (95% CI:
7.4-12.8; Table 4 
Indirect Treatment Comparisons
Using unadjusted data, the pooled incremental gain in letters for ranibizumab monotherapy over laser monotherapy in RESPOND and RESTORE was 6.6 letters (standard error 1.10) ( Table 5 ). The BCVA mean gain for aflibercept monotherapy over laser monotherapy in VIVID-DME/VISTA-DME [13] was 10.0 letters (95% CI: 8.3-11.7; Table 5 ). This compares with the predicted BCVA gain, using adjusted data, in ranibizumab monotherapy compared with laser monotherapy of 9.9 letters (95% CI:
7.3-12.4; see Table 4 ). Using those estimates, there was no statistically significant difference in letters gained at 12 months between ranibizumab and aflibercept (0.1-letter difference; 95% CI: -2.9 to 3.2; P = 0.94; Fig. 2 ). There was also no statistically significant difference between the gain with Fig. 1 Ranibizumab 0.5 mg pro re nata versus laser monotherapy. Predicted change in BCVA (95% confidence interval) from baseline to month 12 if patients in RESPOND [11] and RESTORE [12] had similar baseline characteristics to those in VIVID-DME/ VISTA-DME [13] . Results are shown after adjusting baseline characteristics using the pooled aflibercept 2.0 mg every 8 weeks baseline characteristics from VIVID-DME/ VISTA-DME for ranibizumab predictions and pooled laser monotherapy baseline characteristics from VIVID-DME/VISTA-DME for laser monotherapy predictions. BCVA best-corrected visual acuity, CRT central retinal thickness ranibizumab and that with aflibercept in any of the other models. Model 5 (RESTORE CRT adjustment model) showed the largest difference between aflibercept and ranibizumab, although this was non-significant (P = 0.54).
DISCUSSION
Our model predicted that, if patients in RESPOND/RESTORE had similar BCVA and CRT as in VIVID/VISTA, the incremental letter gains of ranibizumab 0.5 mg over laser would have been greater than those observed in RESTORE/RESPOND. More specifically, the ranibizumab incremental response to laser monotherapy would have been greater than the unadjusted data by a margin of 3.3 letters.
The main driver of this change in response was the difference in baseline CRT between RESPOND/RESTORE and VIVID-DME/ VISTA-DME. Baseline CRT also had a higher impact on outcomes for laser monotherapy than for ranibizumab. Specifically, if two patients undergoing laser monotherapy had a difference of 100 lm in baseline CRT, BCVA gain would be, on average, 2.3 letters less for the patient with the higher baseline CRT. A similar relationship between baseline CRT and laser Table 5 Incremental number of letters gained with aflibercept treatment compared with laser monotherapy in patients from RESPOND/RESTORE [11, 12] or from VIVID-DME/VISTA-DME [13] monotherapy was observed in VIVID-DME/ VISTA-DME. Patients receiving laser monotherapy with a baseline CRT C400 lm gained 3 more letters than patients with a baseline CRT \400 lm [22] . Protocol T also found a substantial impact of CRT at baseline (P = 0.01) [9] . For instance, patients receiving aflibercept with a baseline CRT C400 lm gained 5.3 more letters than patients with a baseline CRT \400 lm and patients receiving ranibizumab 0.3 mg with a baseline CRT C400 lm gained 2.3 more letters than patients with a baseline CRT \400 lm. The incremental gains in BCVA using ranibizumab over laser monotherapy ranged from 9.9 to 10.0 letters across models 1-4, which used data from RESPOND and RESTORE, the narrow range showing the robustness of the base case model results.
Furthermore, additional variables used across models were not statistically different between the trials of interest. Across all models, model 5 had the largest impact with a predictive gain of 9.1 letters, while model 4 had the smallest impact, producing a predictive gain of 9.9 letters. Nevertheless, the value from model 5 remained well above the unadjusted gain of 6.6 letters.
The absolute letter gains at month 12 as well as the differences in letter gain between sub-groups (patients with a baseline BCVA of \69 letters versus those with a baseline BCVA of C69 letters) are less pronounced in our analyses than in Protocol T.
The current analysis underlines the importance of adjusting for key confounders when comparing clinical trial data. If the unadjusted results from RESPOND/RESTORE and VIVID-DME/VISTA-DME are compared in a naïve indirect treatment comparison, aflibercept would appear statistically superior to ranibizumab 0.5 mg PRN. However, this analysis demonstrates that this statistical difference is driven by differences in patient characteristics between trials.
Some remaining unobserved heterogeneity may exist between studies even after adjusting for key baseline characteristics. More details on the study limitations are given in the online supplementary material. Two network meta-analyses in DME have been published [23, 24] . Additional research could include using the adjusted clinical trials outcomes of the analysis to update the network meta-analyses. 
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